Shingles, commonly known as herpes
zoster, is a virus that attacks the brain's cranial nerves. It's caused by the
varicella zoster virus, which is also responsible for chicken pox. Because the
virus can remain dormant in the human body for several years, everyone who has
had chicken pox before is at risk of acquiring shingles. According to the
Centers for Disease Control and Prevention (CDC), one million cases of shingles
were reported in the United States in 2018. Furthermore, the Centers for
Disease Control and Prevention (CDC) estimates that one out of every three
people in the United States will develop shingles at some point in their lives.
The Shingles
Vaccine Market has extended across the globe, with Europe, North
America, the Middle East and Africa, Asia Pacific, and Latin America all having
a share. In the next years, the North American region is expected to occupy a
prominent position in the market. The presence of important competitors in the
region has contributed to the market's growth. Between 2016 and 2024, North
America and Europe are estimated to account for the majority of the market. The
market in North America is likely to rise because to rising demand in the
United States, while the market in Europe is expected to grow due to increased
therapeutic demand from the European Union.
 |
| Shingles Vaccine Market |
The risk of shingles increases with
age, with the majority of occurrences occurring in adults over the age of 40.This
is primarily due to a weakened immune system as a result of increased stress
and insufficient consumption of vital nutrients to maintain immunity. Skin
rashes, nerve discomfort, eyesight loss, cold, upset stomach, muscle weakness,
skin infection, and scarring are some of the symptoms. Antiviral medications
such as acyclovir, valacyclovir, and famciclovir are used to treat shingles.
These medications aid in reducing the length and intensity of the sickness.
Furthermore, analgesics may aid in pain relief.
Over the projected period, the Asia
Pacific shingles
vaccine market is expected to develop at the fastest rate. In the
region, particularly in China and India, there is a large potential market that
has to be exploited. Companies would benefit from active marketing and
differential pricing to strengthen their market position in Asia Pacific.
The FDA compelled Shingrix's maker,
GlaxoSmithKline (GSK), to update the Prescribing Information to add the
following text in the Warnings and Precautions section: During the 42 days
following Shingrix vaccination, an elevated risk of GBS was observed in a
postmarketing observational research.
Consumer demand for the shingles
vaccine Shingrix has caused a shortage due to its effectiveness. The
vaccination is intended for anyone over the age of 50, particularly those who
had chickenpox as a child. According to experts, the vaccine is still available
at pharmacies and doctors' offices. Shingrix, a new vaccination that is
particularly efficient in preventing shingles, is now available. The Centers
for Disease Control and Prevention (CDC) recommends getting this vaccine if
you're 50 or older and have a healthy immune system, regardless of whether
you've ever had shingles.
Because you were inoculated against
the virus, Romine thinks it's unlikely you'd acquire shingles. Shingles isn't
communicable in and of itself, but the varicella-zoster virus is. In people who
have never had chickenpox or received the chickenpox vaccination, this could
result in chickenpox.
Comments
Post a Comment